Aggregated price index with volume information
Summary:
- Medical Distributors stocks down 0.3% on average while median return down -0.1% in a day
- Medical Distributors stocks up 1.9% on average while median return up 1.3% in a week
- Medical Distributors stocks down 3.6% on average while median return down 2.7% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $HLF 26.8%, $MCK 8.8%, $HSIC 6.6%, $PDCO 1.1%
- 1M losers are : Losers for past month are $CAH -6.5%, $APLS -13.0%, $ACET -20.8%, $OMI -22.6%
- 1W winners are : Winners for past week are $ACET 8.8%, $HLF 2.4%, $HSIC 1.8%, $PDCO 1.8%
- 1W losers are : Losers for past week are $OMI -0.1%, $CAH -0.5%, $APLS -1.6%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 9.2%, for the past 3 months is 10.1%
In the past month for a 5 days rolling window, the highest corrrelation is 26.3%, the lowest correlation is -4.8%, the latest correlation is -1.2%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 48.1% between CAH and OMI
The lowest correlation is -24.9% between ABC and MCK
IRVING, Texas, May 07, 2024--McKesson Corporation (NYSE: MCK) has released its fiscal 2024 fourth quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...
Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 0% and 7.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Dental and medical products distributor Henry Schein missed first-quarter revenue estimates on Tuesday, weighed by lingering effects of last year's cybersecurity incident that disrupted its manufacturing and distribution divisions. The company had said on Oct. 15 it took some of its systems offline after a cyber attack, contacted law enforcement authorities and engaged outside experts to investigate the breach. Henry Schein, which supplies dental products such as implants, posted revenue of $3...
Aligns with EPS Projections While Enhancing Strategic Initiatives